How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

32,112 results for

Hypertension Evaluation History

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Pediatric Pulmonary Hypertension

Society, a panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension. This publication presents the results of extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension. (Circulation. 2015;132:2037-2099. DOI: 10.1161/CIR.0000000000000329.) Key Words: AHA Scientific Statements (...) on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society Downloaded from http://ahajournals.org by on March 27, 20192038 Circulation November 24, 2015 1. Introduction 1.1. Rationale and Goals This guidelines document addresses approaches to the evalu- ation and treatment of pulmonary hypertension (PH) in chil- dren, defined as a resting mean pulmonary artery pressure (mPAP) >25 mm Hg beyond

Full Text available with Trip Pro

2015 American Heart Association

142. Treatment of Hypertension in Patients With Coronary Artery Disease

Studies and Clinical Trials 1383 3.2.3. Clinical Trials to Specifically Evaluate Lower BP Goals 1384 3.2.4. Lower BP Goals and Diabetes Mellitus 1384 3.2.5. Lower BP Goals for the Prevention of Stroke 1385 3.2.6. The Elderly 1385 3.2.7. Conclusions 1385 3.3. Recommendations 1386 Management of Hypertension in Patients With CAD and Stable Angina 1386 4.1. Pharmacological Therapy 1386 4.1.1. β-Blockers 1386 4.1.2. Calcium Channel Blockers 1386 4.1.3. ACE Inhibitors 1387 4.1.4. Angiotensin Receptor (...) groups. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure uses the traditional definition of hypertension as an SBP of ≥140 mm Hg or a DBP of ≥90 mm Hg and/or the current use of antihypertensive medication. With this definition, an estimated 65 million adult Americans, or nearly one fourth of the adult population of the United States, have hypertension. Another quarter of the population have prehypertension, defined as an SBP

Full Text available with Trip Pro

2015 American Heart Association

143. Pediatric Pulmonary Hypertension: ATS/AHA Clinical Practice Guidelines

, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. †For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. by guest on March 15, 2016 http://circ.ahajournals.org/ Downloaded from Abman et al Pediatric Pulmonary Hypertension 5 available evidence as Level B when data were (...) Heart Association and American Thoracic Society, a panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension. This publication presents the results of extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension. (Circulation. 2015;132:00-00. DOI: 10.1161/CIR.0000000000000329

2015 American Thoracic Society

144. Beta-blockers in Uncomplicated Hypertension: Is it Time for Retirement?

into use and have become the mainstay in the treatment of hypertension. In the subsequent 40 years, beta-blockers battled high blood pressure in the front-lines. But in 2014, after a 10-year hiatus, the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC) released its 8th guideline on treating hypertension ( ). In these new recommendations, beta-blockers were relegated to second-line treatment, behind thiazide-diuretics, calcium channel blockers (CCB (...) is an Internal Medicine Resident at NYU Langone Medical Center Peer reviewed by Lois Anne Katz, MD, Medicine, NYU Langone Medical Center Image courtesy of Wikimedia Commons References Hamdy RC . Hypertension: a turning point in the history of medicine…and mankind. South Med J. 2001;94(11):1045-7. Ripley TL, Saseen JJ . beta-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother. 2014;48(6):723-33. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie

2015 Clinical Correlations

145. Cohort study: Aiming too high or too low? Searching for the appropriate therapeutic thresholds in hypertension is not over yet

at baseline (sitting BP >140/90 mm Hg, or history of hypertension), without history of CV disease were identified. The participants were classified as low (reference, <120 mm Hg), standard (120–139 mm Hg) and elevated (>139 mm Hg) SBP, and, additionally, as those below and above 160 mm Hg. The primary outcome was a composite CV event of myocardial infarction, CV death, heart failure and ischaemic stroke. The authors clearly described the selection process and how the CV end points during follow-up were (...) with the low-normal SBP group. It should be noted that the authors did not report the incidence of major CV events in normotensive participants, so the potential impact of hypertension with a satisfactory BP control on the development of CV disease could not be evaluated. In summary, when properly treated to the SBP threshold below 160 mm Hg, CV risk associated with uncomplicated hypertension did not substantially differ across increasing strata of office SBP. In contrast, hypertensive patients

Full Text available with Trip Pro

2015 Evidence-Based Medicine (Requires free registration)

146. Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation (...) of Splenic Metabolic Activity With 18FDG-PET in Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02572765 Recruitment Status : Not yet recruiting First Posted : October 9, 2015 Last Update Posted : December 18

2015 Clinical Trials

147. Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension

Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02647034 Recruitment Status : Unknown Verified January 2016 by National Taiwan University Hospital. Recruitment status was: Recruiting First Posted : January 6, 2016 Last

2015 Clinical Trials

148. Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients

Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has

2015 Clinical Trials

149. Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions

Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02552485 Recruitment Status : Completed First Posted : September 17, 2015 Last Update Posted : December 31, 2015 Sponsor: Universitaire Ziekenhuizen Leuven

2015 Clinical Trials

150. 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension The safety and scientific validity of this study is the responsibility

2015 Clinical Trials

151. Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms (...) x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has

2015 Clinical Trials

152. Migraine and Vasospasm in Glaucoma: Age-Related Evaluation of 2027 Patients With Glaucoma or Ocular Hypertension. (PubMed)

Migraine and Vasospasm in Glaucoma: Age-Related Evaluation of 2027 Patients With Glaucoma or Ocular Hypertension. To evaluate frequency of migraine, vasospasm (VS), family history (FH) of migraine, and family history of glaucoma (FHG) in different types of glaucoma in relation to age and stage of visual field loss (VFL) at diagnosis.A total of 2170 patients with glaucoma or ocular hypertension (OH) were interviewed by using standardized questions concerning FHG, age at diagnosis, and potential

Full Text available with Trip Pro

2015 Investigative Ophthalmology & Visual Science

153. Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. (PubMed)

Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. The objective of this study was to evaluate the efficacy and safety of the lercanidipine/valsartan combination compared with lercanidipine monotherapy in patients with hypertension.Part 1 of this study was the randomized, multicenter, double (...) -blind, parallel group, Phase III, 8-week clinical trial to compare superiority of lercanidipine 10 mg/valsartan 80 mg (L10/V80) and lercanidipine 10 mg/valsartan 160 mg (L10/V160) combinations with lercanidipine 10 mg (L10) monotherapy. At screening, hypertensive patients, whose diastolic blood pressure (DBP) was >90 mm Hg after 4 weeks with L10, were randomized to 3 groups of L10, L10/V80, and L10/V160. The primary end point was the change in the mean sitting DBP from baseline (week 0) after 8

2015 Clinical therapeutics

154. A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy The safety and scientific validity of this study is the responsibility

2015 Clinical Trials

155. A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy The safety and scientific validity of this study

2015 Clinical Trials

156. A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. (ALIVE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2015 Clinical Trials

157. Diagnosis, Evaluation and Follow-up of Asymptomatic Microhematuria (AMH) in Adults

benign cause. A positive dipstick does not define AMH, and evaluation should be based solely on findings from microscopic examination of urinary sediment and not on a dipstick reading. A positive dipstick reading merits microscopic examination to confirm or refute the diagnosis of AMH. Expert Opinion 2. The assessment of the asymptomatic microhematuria patient should include a careful history, physical examination, and laboratory examination to rule out benign causes of AMH such as infection (...) up or those with other risk factors for carcinoma in situ (e.g., irritative voiding symptoms, current or past tobacco use, chemical exposures), cytology may be useful. Option (Evidence Strength Grade C) 16. Blue light cystoscopy should not be used in the evaluation of patients with asymptomatic microhematuria. Recommendation (Evidence Strength Grade C) 17. If a patient with a history of persistent asymptomatic microhematuria has two consecutive negative annual urinalyses (one per year for two

2016 American Urological Association

158. Management of Hypertension (HTN) in Primary Care

, herbal remedies, and dietary supplements, some of which may raise blood pressure or interfere with the effectiveness of antihypertensive medications 10. History of alcohol and illicit drug use (especially cocaine and other stimulants) 11. Psychosocial and environmental factors (e.g., family situation, employment status and working conditions, level of comprehension) that may influence hypertension controlOctober 2014 Page 24 of 135 A physical exam should include an evaluation for signs of secondary (...) hypertension or hypertensive organ damage. At a minimum, vital signs should include height, weight, and two or more blood pressure readings to include one in each arm, with the patient seated. All hypertensive patients should have a thorough history and physical examination, but need only a limited number of routine investigations. It is beyond the scope of these guidelines to discuss every detail of the clinical evaluation, but it may be useful to summarize the aims, which are to elicit and document

2014 VA/DoD Clinical Practice Guidelines

159. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Haven, CT; Johns Hopkins University 450 Evidence-Based Medicine [ 146#2 CHEST AUGUST 2014 ] S umma r y o f Reco mmenda tio n s Pha r maco logic Th erapy for Pulmonary Arterial Hypertension in Adults 1. We suggest that the severity of a pulmonary arterial hypertension (PAH) patient’s disease be evaluated in a systematic and consistent manner, using a combination of World Health Organization (WHO) functional class (FC), exercise capacity, echocar- diographic, laboratory and hemodynamic vari- ables (...) that drug therapy be chosen on the basis of a methodical evaluation of disease severity and the risk for further short-term deterioration. Th e optimal method of evaluation has not been studied. Despite variability in clinicians’ approaches, 7 the WHO FC ( Table 2 ) 18 provides a patient-centered means of assessing disease TABLE 2 ] World Health Organization Functional Classi? cation of Patients With Pulmonary Hypertension Classi? cation Class I: Patients with PH but without resulting limitation

2014 American College of Chest Physicians

160. Essential Hypertension

) Associated Conditions • Sleep apnea Rationale for Recommendations Recommendations are organized under headings for: • Diagnosis of hypertension • Initial evaluation of newly diagnosed patient • Treatment of hypertension • Monitoring blood pressure control Diagnosis of Hypertension Performing BP measurement. BP readings need to be performed accurately to provide useful information. BP in the office should be checked after 5 minutes of sitting quietly in a chair, with feet on the floor, and arm supported (...) masked hypertension, resulting in more aggressive medication regimens and improved cardiovascular outcomes. Currently, reimbursement for ABPM by Medicare is covered only for suspected WHC, defined by 3 or more office visit BPs >140/90 mm Hg, at least two documented BPs outside the office 30 kg/m 2 ) • Physical inactivity • Dyslipidemia • Diabetes • Estimated GFR 55 for men, >65 for women) • Family history of premature cardiovascular disease (men 3) drugs are needed, consider referral

2014 University of Michigan Health System

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>